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Treatment of Severe Pneumonia in Hospitalized Patients: Results of a
Multicenter, Randomized, Double-Blind Trial Comparing
Intravenous Ciprofloxacin with Imipenem-Cilastatin
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Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia.
In this prospective, randomized, double-blind, multicenter trial, which included an intent-to-treat analysis, a total
of 405 patients with severe pneumonia were enrolled. The mean APACHE II score was 17.6, 79%o of the patients
required mechanical ventilation, and 78% had nosocomial pneumonia. A subgroup of 205 patients (98
ciprofloxacin-treated patients and 107 imipenem-treated patients) were evaluable for the major efficacy
endpoints. Patients were randomized to receive intravenous treatment with either ciprofloxacin (400 mg every 8
h) or imipenem (1,000 mg every 8 h), and doses were adjusted for renal function. The primary and secondary
efficacy endpoints were bacteriological and clinical responses at 3 to 7 days after completion of therapy.
Ciprofloxacin-treated patients had a higher bacteriological eradication rate than did imipenem-treated patients
(69 versus 59%o; 95% confidence interval of - 0.6%, 26.2%; P = 0.069) and also a significantly higher clinical
response rate (69 versus 56%; 95% confidence interval of3.5%, 28.5%; P = 0.021). The greatest difference between
ciprofloxacin and imipenem was in eradication of members of the family Enterobateriaceae (93 versus 65%; P =
0.009). Stepwise logistic regression analysis demonstrated the following factors to be associated with bacterio-
logical eradication: absence of Pseudomonas aeruginosa (P < 0.01), higher weight (P < 0.01), a low APACHE IH
score (P = 0.03), and treatment with ciprofloxacin (P = 0.04). When P. aeruginosa was recovered from initial
respiratory tract cultures, failure to achieve bacteriological eradication and development of resistance during
therapy were common in both treatment groups (67 and 33% for ciprofloxacin and 59 and 53% for imipenem,
respectively). Seizures were observed more frequently with imipenem than with ciprofloxacin (6 versus 1%; P =
0.028). These results demonstrate that in patients with severe pneumonia, monotherapy with ciprofloxacin is at
least equivalent to monotherapy with imipenem in terms of bacteriological eradication and clinical response. For
both treatment groups, the presence of P. aeruginosa had a negative impact on treatment success. Seizures were
more common with imipenem than with ciprofloxacin. Monotherapy for severe pneumonia is a safe and elfective
initial strategy but may need to be modified if P. aeruginosa is suspected or recovered from patients.
Despite improvements in antimicrobial chemotherapy and
supportive care, bacterial pneumonia, whether nosocomial or
community acquired, remains an infection with substantial
mortality. Nosocomial pneumonia accounts for about 15% of
* Corresponding author. Present address: Beth Israel Hospital, 330
Brookline Avenue, Boston, MA 02215. Phone: (617) 735-4710. Fax:
(617) 735-2978.
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Louisiana State University Medical Center, New Orleans; Principal
Investigator Matthew E. Levison, Coinvestigators Oksana Korzeni-
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Philadelphia; Principal Investigator Curtis N. Sessler, Coinvestigators
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all hospital-acquired infections (20) and is the most common
nosocomial infection among patients cared for in intensive
care units (10). In several recent reviews, mortality due to
nosocomial pneumonia has been estimated to be 30 to 70% (6,
11, 12, 26). However, most prospective antimicrobial clinical
trials have been conducted in patient populations with mortal-
ity rates ranging from 4 to 33% (23, 28, 29, 31). Severe cases of
community-acquired pneumonia usually necessitate hospital-
ization and have been associated with a mortality rate as high
as 21%, even among patients without obvious preexisting
immune deficits (37, 47).
A key component of the treatment for severe bacterial
pneumonia is administration of an appropriate parenteral
antibacterial regimen. The initial choice of agents is typically
empiric, since the results of sputum and blood cultures are
usually not available when therapy is started. The clinical
diagnosis of pneumonia based upon conventional criteria only
(i.e., fever, leukocytosis, new infiltrates on chest roentgeno-
gram, and purulent sputum) may be inaccurate (2, 7, 12, 14, 44,
53). Moreover, results obtained by culturing sputum aspirated
from the airways of endotracheally intubated, mechanically
ventilated patients may lack specificity compared with results
obtained by more invasive means of sampling bronchial secre-
tions (2, 12, 42, 45, 46). In addition, pneumonia in mechani-
cally ventilated patients is often polymicrobial (18). For exam-
ple, Fagon et al. found that multiple organisms were isolated
from 40% of study patients (12). Consequently, broad-spec-
trum antimicrobial coverage is generally recommended for the
empirical or initial treatment of severe bacterial pneumonia
(18).
Imipenem and ciprofloxacin are two broad-spectrum anti-
microbial agents belonging to different chemical classes which
have been evaluated as single agents for the treatment of
pneumonia (19, 21, 23, 27, 38-40, 43, 49, 50). Imipenem is a
carbapenem antibiotic which possesses excellent in vitro activ-
ity against a wide range of pathogens implicated in the etiology
of severe pneumonia, including methicillin-susceptible Staph-
ylococcus aureus, Streptococcus pneumoniae, members of the
family Enterobacteriaceae, and Haemophilus influenzae (34).
This drug also manifests good in vitro activity against Pseudo-
monas aeruginosa (34). Ciprofloxacin is a fluorinated quin-
olone antimicrobial agent which demonstrates excellent in
vitro activity against H. influenzae, members of the family
Enterobacteriaceae, including Enterobacter cloacae, methicillin-
susceptible S. aureus, and P. aeruginosa, and moderate activity
against S. pneumoniae (51, 52). Ciprofloxacin, unlike 3-lactam
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antibiotics, reaches levels in bronchial secretions above those
in serum (5), a property that might enhance its therapeutic
efficacy in the treatment of pneumonia.
Intravenous (i.v.) ciprofloxacin is indicated for the treatment
of mild-to-moderate lower respiratory tract infections at a
dosage of 400 mg every 12 h. Our study was designed to assess
treatment of patients with severe nosocomial or community-
acquired pneumonia based on stringent entry criteria. In
patients with severe pneumonia, because of the severity of the
illness or the possible presence of pulmonary pathogens that
may be only moderately susceptible to ciprofloxacin, adminis-
tration of a higher dose might be warranted (38). Therefore,
the goal of the present study was to compare the efficacy and
safety of ciprofloxacin (400 mg every 8 h) with those of
imipenem (1,000 mg every 8 h), an antibiotic frequently used in
the treatment of patients hospitalized with severe pneumonia
(39).
Previous clinical trials conducted to assess the efficacy of
antibiotics for the treatment of pneumonia have been difficult
to evaluate. Flaws of these studies have included lack of a
double-blind design, exclusion of patients with underlying
conditions associated with higher mortality, small sample sizes,
and absence of intent-to-treat analyses (15-17, 27, 39-41, 43,
44). Other trials allowed inclusion of patients with a variety of
lower respiratory tract infections and therefore did not enroll
a clearly defined patient population (15, 17, 21, 23, 37, 41, 43,
48, 49). In the present study, we sought to avoid these
criticisms and, accordingly, enrolled a relatively homogeneous
population in which severity of illness measured by objective
indices of respiratory dysfunction served as the entry criterion.
The study was conducted and analyzed under fully blind
conditions.
(This work was presented in part at the 33rd Interscience
Conference on Antimicrobial Agents and Chemotherapy, New
Orleans, La., 17 to 20 October 1993.)
MATERLILS AND METHODS
Study design. This was a multicenter, double-blind, random-
ized trial comparing i.v. ciprofloxacin with i.v. imipenem for
the treatment of patients hospitalized (usually in intensive care
units) with severe pneumonia. Twenty medical centers in the
United States participated in the study and enrolled patients
from May 1990 through July 1992. The study was approved by
the institutional review board at each participating center.
Informed consent was obtained from each patient (or an
appropriate third party).
The objective of the study was to compare ciprofloxacin with
imipenem for the treatment of severe pneumonia, with thera-
peutic equivalence being defined as a difference in bacterio-
logical eradication rates of less than 10 percentage points
(10%). The sample size objective to test this hypothesis for
efficacy was 100 evaluable patients in each treatment group.
With a computer-generated code, patients were randomized
to receive either i.v. imipenem-cilastatin or i.v. ciprofloxacin.
Prior to randomization, patients were stratified on the basis of
whether pneumonia was nosocomial or community acquired.
Nosocomial pneumonia was defined as pneumonia developing
after 48 or more h of hospitalization for another problem. All
other cases of pneumonia, including those acquired in nursing
homes, were considered community acquired.
Patient selection. The study inclusion criteria were as fol-
lows: 218 years of age; compromised respiratory function
requiring a fractional inspired oxygen concentration of .0.35
to maintain an arterial oxygen tension of .60 mm Hg or being
on mechanical ventilation at any oxygen concentration; at least
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one symptom of bronchopulmonary infection (dyspnea; fever,
hypothermia, or rigors; increase or new onset of cough;
pleuritic chest pain; increase in sputum production or purulent
sputum); new pulmonary infiltrate on chest roentgenogram
thought to be due to infection; sputum Gram stain showing
>25 polymorphonuclear neutrophils and <10 squamous cells
and potentially pathogenic bacteria. The study exclusion crite-
ria were as follows: allergy to a fluoroquinolone or ,B-lactam;
pregnancy or nursing mother status; concurrent treatment with
antimicrobial agents with activity spectra similar to those of the
study drugs; absolute neutrophil count of .1,000 cells per
mm3; prior antimicrobial treatment of the study infection for
more than 24 h unless a persistent positive culture is docu-
mented; treatment with an investigational drug within 30 days
prior to study enrollment or previous enrollment in this study.
These criteria were designed to selectively enroll critically ill
patients with pneumonia caused by identifiable pathogens.
Treatment. A high-dosage regimen of imipenem-cilastatin
(1,000 mg every 8 h) and ciprofloxacin (400 mg every 8 h) was
designed for the treatment of susceptible pathogens. A lower-
dosage schedule of the study agents (400 mg/12 h for cipro-
floxacin and 500 mg/6 h for imipenem) was designed for the
treatment of highly susceptible pathogens (imipenem dosing
was based on package insert information). All patients were to
be started on the high-dosage schedule. However, once sus-
ceptibility data were available, patients could be changed to the
lower-dosage schedule at the discretion of the principal inves-
tigator at each center. Only a single change in the schedule
(i.e., from the high to the lower dosage) was permitted by the
protocol. Both schedules allowed for adjustment of the study
medication dose for patients with renal impairment. This was
performed by the study pharmacist (unblinded) on the basis of
estimated creatinine clearance.
The study antibiotics were diluted by the research pharma-
cist to a volume of at least 150 ml with normal saline or a 5%
dextrose solution. The study drug was infused i.v. over a period
of 40 to 60 min.
Administration of antifungal agents, antiviral agents, topical
antimicrobial agents, and oral vancomycin was permitted by
the protocol. If aspiration was suspected as the etiology of
pneumonia or if the sputum Gram stain suggested the pres-
ence of anaerobic bacteria, then administration of metronida-
zole was permitted for those patients randomized to cipro-
floxacin treatment. Patients randomized to imipenem received
a placebo infusion to maintain the blind condition. Use of i.v.
vancomycin was permitted at the investigator's discretion for
patients in both treatment groups with sputum cultures show-
ing mixed gram-positive and gram-negative organisms or in
patients with gram-positive bacteremia. If i.v. vancomycin was
utilized, then the bacteriologic response to the study drug of
any gram-positive organisms was excluded from efficacy anal-
yses. The administration of other systemically active antimicro-
bial chemotherapy was prohibited by the protocol.
Bacteriological procedures. Appropriate cultures for isola-
tion, identification, and susceptibility testing of organisms
thought to be involved in the infectious process were obtained
no more than 48 h prior to initiation of treatment. Sputum was
the primary sample used for bacteriological documentation of
pneumonia, although blood cultures were also obtained to
document bacteremia. Susceptibility of bacterial isolates to the
study drugs was determined by standard methods, and the
results were assessed in accordance with published guidelines
of the National Committee for Clinical Laboratory Standards
(32, 33). Routine cultures for Legionella pneumophila were not
required by the protocol.
Evaluations for efficacy and safety. Patients were considered
evaluable for both bacteriological and clinical responses if they
met inclusion criteria, had at least one pretreatment patho-
genic organism susceptible to both of the study drugs, and
satisfied other evaluability criteria.
The primary measure of study drug efficacy was bacteriolog-
ical response at the end of therapy, which was defined as the
time between days 3 and 7 posttherapy to allow for elimination
of any residual antimicrobial drug which might prevent detec-
tion of persisting pathogenic bacteria. Bacteriological re-
sponses were classified as eradication (elimination of pre-
therapy organisms), presumed eradication (no material
available for culture), persistence (continued isolation of the
causative organisms), superinfection (acquisition of a new
pathogen requiring treatment during study therapy), and inde-
terminate (bacteriological response to the study drug was not
evaluable) (4, 8).
Clinical response to therapy was a major secondary endpoint
of the trial. Clinical response at 3 to 7 days after completion of
therapy was assessed by each principal investigator. Clinical
responses were classified as resolution (disappearance of signs
and symptoms related to the infection), failure (insufficient
lessening of the signs and symptoms of infection such that
additional therapy was necessary), and indeterminate (no
evaluation possible) (4, 8). If during therapy the infection was
improving but a patient died as a result of another disease
process or study treatment of a patient was prematurely
discontinued because of an adverse event, then the clinical
response was considered improvement. If the infection was not
improving or was thought to have contributed to the patient's
demise, then the clinical response was graded as failure.
All adverse clinical events or laboratory abnormalities oc-
curring during treatment or within 7 days of discontinuation of
study medication were recorded and assessed by the principal
investigator with regard to the relationship to the study drug
and the severity of the event. Theophylline concentrations in
serum were routinely monitored in patients receiving concom-
itant theophylline. Patient survival was recorded during ther-
apy and for 30 days following drug discontinuation.
Premature termination of treatment. Any patient who re-
ceived the study drug for less than 5 full days of treatment was
not considered in the efficacy-evaluable analyses unless there
was clear evidence of therapeutic failure. If the patient did not
respond clinically or if a superinfection developed, treatment
with the study drug was discontinued and other appropriate
therapy was instituted. Patients dying within the first 48 h of
therapy were classified as indeterminate, not as treatment
failures, and were included in the analyses performed on the
intent-to-treat population. These decisions were made before
unblinding of the study.
Statistical analyses. Results were analyzed to determine the
comparative efficacy and safety of the two study drugs. Primary
efficacy analyses were performed on only those cases meeting
predetermined criteria for evaluability (efficacy-evaluable pop-
ulation). In addition, the same analyses for efficacy and all
safety analyses were performed on the intent-to-treat popula-
tion. All patients who received at least one dose of the study
drug were included in the intent-to-treat population. No
interim analysis was performed, and all data were processed by
Miles Inc. All major variables were defined explicitly in the
protocol, and no changes in the data base were made subse-
quent to breaking of the treatment allocation code.
The primary efficacy variable was bacteriological response at
3 to 7 days posttherapy. Clinical response at the same time
point was considered a secondary outcome variable. For these
two variables, 95% confidence intervals (CI) were constructed
for the differences in eradication rates or resolution rates
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between the two treatment groups, respectively. A CI that did
not include -10% would indicate treatment equivalence; a
lower limit greater than 0% would indicate ciprofloxacin
superiority. Indeterminate responses were not included in the
calculation of either eradication rates or resolution rates.
Overall tests of baseline comparability between the two
treatment groups were conducted for several categorical vari-
ables by using the Cochran-Mantel-Haenszel test to adjust for
the multicenter nature of the trial. Cochran-Mantel-Haenszel
tests were also used for the efficacy variables. A Mantel-
Haenszel weighting scheme was used to compute the CI (30).
This method requires at least one evaluable patient per
treatment group per center, resulting in the exclusion of five
centers from the primary analyses; this decision was made
prior to breaking of the treatment allocation code. To deter-
mine whether bacteriological and clinical response results were
poolable across centers, a treatment-by-center interaction test
was performed by the method of Zelen (54).
Logistic regression was used to determine whether the
treatment group or any clinical factor was a significant predic-
tor of bacteriological and clinical responses. First, each vari-
able that potentially affected eradication or resolution rates
was included in logistic regression models to assess the ability
of that variable to predict outcome (univariate model). Then,
a stepwise logistic regression procedure was used to identify
the best combination of variables by utilizing those variables
that were significant predictors of outcome in the univariate
model. Finally, treatment group was added to the best model
selected by this stepwise procedure to determine whether it
had significant explanatory value.
RESULTS
Patient characteristics. Twenty centers contributed to the
study, enrolling 405 patients (205 in the ciprofloxacin treat-
ment group and 200 in the imipenem treatment group). Three
patients never received study medication after being random-
ized; the other 402 patients received either ciprofloxacin (n =
202) or imipenem (n = 200), and these patients constituted the
intent-to-treat population. One patient was randomized to the
imipenem treatment group but actually received ciprofloxacin;
this patient was analyzed as part of the ciprofloxacin treatment
group.
Of the 402 patients in the intent-to-treat population, 205 (98
in the ciprofloxacin treatment group and 107 in the imipenem
treatment group) met the predetermined criteria for the
efficacy-evaluable population. The reasons for excluding pa-
tients from the primary efficacy analyses are shown in Table 1.
All determinations of evaluability were made prior to unblind-
ing.
Overall, the ciprofloxacin and imipenem treatment groups
were statistically comparable with respect to almost all demo-
graphic variables (Table 2). This was true for both the efficacy-
evaluable and the intent-to-treat populations. At the time of
enrollment, both treatment groups were similar with respect to
severity of illness, as quantitated by APACHE II scores (23a),
and degree of pulmonary dysfunction, as estimated by the
arterial oxygen tension/fractional inspired oxygen concentra-
tion ratio and the alveolar-arterial oxygen tension gradient.
Approximately four-fifths of both the efficacy-evaluable and
intent-to-treat patients were classified as having nosocomial
pneumonia and were being mechanically ventilated at the time
of randomization.
Treatment. Among patients considered to be efficacy evalu-
able, the mean durations of treatment were 10.5 days in the
ciprofloxacin group and 10.1 days in the imipenem group (P =
TABLE 1. Reasons for exclusion from efficacy-evaluable analysis
No. (%) of patients
Reason for exclusion treated with:
Ciprofloxacina Imipenemb
No causative organism isolated 36 (17.6) 23 (11.5)
pretherapy
Organism resistant to study drug 9 (4.4) 10 (5.0)
Five study sites excluded because 4 (2.0) 4 (2.0)
of Mantel-Haenszel statistical
requirements
Patients with indeterminate re- 3 (1.5) 8 (4.0)
sponses for both bacteriological
and clinical efficacy endpoints
Protocol violations
Inclusion or exclusion criteria 20 (9.8) 9 (4.5)
Required cultures not obtained 11(5.4) 13 (6.5)
Inadequate duration of treat- 7 (3.4) 12 (6.0)
ment
Antimicrobial therapy within 7 (3.4) 5 (2.5)
pretreatment window
No susceptibility testing done 4 (2.0) 4(2.0)
pretherapy
Concomitant antimicrobial ther- 2 (1.0) 4 (2.0)
apy (other than pretreatment)
Randomization error 1(0.5) 1(0.5)
Total patients excluded from effi- 104 (51.5) 93 (46.5)
cacy-evaluable populationc
a n = 202. Three patients randomized to the ciprofloxacin treatment group
never received the study medication and are not included.
bn = 200.
Pp = 0.094 (not significant). The P value was calculated with a chi-square test.
0.703). Eighty percent of ciprofloxacin-treated patients and
82% of imipenem-treated patients in the intent-to-treat pop-
ulation received the high-dosage regimen throughout the
entire study. In the efficacy-evaluable population, 76% of
ciprofloxacin-treated and 78% of imipenem-treated patients
received the high-dosage regimen throughout the study. The
mean durations of the high-dosage regimen in the ciprofloxa-
cin and imipenem treatment groups were 9.5 and 8.8 days,
respectively (P = 0.809). Among the patients considered for
the intent-to-treat analyses, the mean durations of treatment
were approximately 1 day shorter for both treatment groups.
In the efficacy-evaluable population, 58 (59.2%) of the
patients in the ciprofloxacin treatment group and 71 (66.4%)
of the patients in the imipenem treatment group had been
treated with nonstudy antimicrobial agents prior to enrollment.
Concomitant antimicrobial agents were employed by 42 (43%)
ciprofloxacin-treated patients and 50 (47%) imipenem-treated
patients in the efficacy-evaluable population. The concomitant
antibacterial agents permitted by the protocol included vanco-
mycin (27 patients) and metronidazole (11 patients) in the
ciprofloxacin treatment group. In the imipenem treatment
group, 31 patients received vancomycin and 16 received a
placebo for metronidazole to maintain the blind condition.
Both gram-positive and gram-negative organisms were isolated
from all of the efficacy-evaluable patients who received vanco-
mycin (11 in the ciprofloxacin treatment group and 8 in the
imipenem treatment group). A few patients in both treatment
groups concomitantly received antibiotics excluded by the
protocol. These patients were evaluated on an individual basis
prior to breaking of the treatment allocation code and were
considered valid for the analyses of efficacy if at least one
pretreatment respiratory pathogen was not susceptible to the
concomitantly administered antibiotic (4, 8).
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TABLE 2. Demographic dat
Variable
No. (%) of:
Males
Females
Mean age (yr)" ± SD
Mean weight (kg)" ± SD
No. (%) of:
Caucasians
Noncaucasians
Duration of hospital stay prior to
enrollment (days)"
Median
Range
Mean P(A-a)02' ± SD
Mean PaO2/FIO" ratio" ± SD
Mean APACHE II score" ± SD
No. (%) of patients with:
Assisted ventilation
Unassisted ventilation
Mean leukocyte count/mm3",
± SD
Mean creatinine concn (mg/dl)"
± SD
No. (%) of patients with':
Nosocomial pneumonia
Community-acquired
pneumonia
No. (%) of patients in ICU or
SICUf
No. (%) of patients from whom
P. aeruginosa isolated"
No. (%) of patients with:
Bacteremia
No. (%) of patients with:
No previous antimicrobial
treatment
Previous antimicrobial
treatment
"Demographic data of study population al
study. None of the differences between the
significant.
"Treated as a continuous variable.
P(A-a)O,, alveolar-arterial oxygen tensi(
dPaO2, arterial oxygen tension; FIG2, fro
tion.
" Two patients in the ciprofloxacin tre
infection sites.
fICU, intensive care unit; SICU, surgical
g Represents the number of patients from
Bacteriological and clinical responses. The bacteriological
and clinical efficacy assessments are presented in Table 3.
a of study population" There were 3 (of 98) ciprofloxacin and 13 (of 107) imipenem
Intent-to-treat population data indeterminate outcomes for bacteriological eradication and 0(of 98) ciprofloxacin and 3 (of 107) imipenem indeterminateCiprofloxacin Imipenem responses for clinical resolution in the efficacy-evaluable pop-
group group ulatio
(oz = 202) (nI = 20)()) nltll.
In the efficacy-evaluable population, ciprofloxacin-treated
patients had a bacteriological eradication rate of 69%, com-
140 (69.3) 142 (71.0) pared with 59% for imipenem-treated patients (95% CI of62 (30.7) 58 (29.0)
- 0.6%, 26.2%; P = 0.069; Table 3). The difference in eradi-
59.9 ± 17.9 59.6 ± 17.6 cation rate between the two treatment groups was not statis-tically significant but did show ciprofloxacin to be statistically
72.7 ± 18.7 71.8 ± 17.8 equivalent to imipenem.
The clinical resolution rates, also shown in Table 3, demon-
strate that in the efficacy-evaluable population, ciprofloxacin-
153 (75.7) 155 (77.5) treated patients had a statistically significantly better clinical
49 (24.3) 45 (22.5) response rate (69%) than the imipenem-treated patients
(56%) (95% CI of 3.5%, 28.5%; P = 0.021). The clinical
response rate in the ciprofloxacin treatment group was higher
7.0 7.0 but not significantly different from that in the imipenem
0-259 0-508 treatment group for the intent-to-treat population (64 versus56%, 95% CI of - 2.1%, 19.6%; P = 0.123). These trends were
222.9 ± 135.6 233.4 ± 139.4 maintained whether patients had community-acquired or nos-
ocomial pneumonia. Of the clinical treatment failures, two-
208.2 ± 96.2 202.8 ± 84.7 thirds of both the ciprofloxacin and imipenem treatment
groups were still clinical failures at a 14- to 28-day posttherapy
17.7 ± 6.5 17.6 ± 6.4 follow-up evaluation, despite treatment with alternative anti-
microbial agents (data not shown).
154 (80.6) 150 (76.9) Multiple organisms were isolated from half of the efficacy-
37(19-4) 45(231) evaluable patients in both the ciprofloxacin and imipenemtreatment groups. Bacteriological and clinical response rates
15.0 ± 7.5 14.7 ± 7.0 were consistently better in both study groups when only a
single respiratory pathogen was isolated. However, presence of
multiple organisms on initial sputum culture was not a signif-
1.28 ± 1.0 1.45 ± 1.3 icant predictor of poor outcome on logistic regression analysis
(Table 4). Not unexpectedly, 80% of patients still had persis-
tent infiltrates on chest X-ray at the end of therapy.
156 (78.0) 156 (78.0) Univariate and multiple logistic regression analyses of
44 44(22.0) efficacy parameters. Bacteriological eradication rates in the
efficacy-evaluable population were further analyzed to exam-
ine the effects of potentially confounding factors on the
160 (79.2) 161 (8(1.5) comparison between ciprofloxacin and imipenem. When po-
tential risk factors for treatment failure were analyzed in a
univariate fashion, three variables were found to have a
47 (23.3) 44 (22.0) statistically significant effect on the eradication rate (Table 4).
The presence of P. aeruginosa, lower body weights, and higher
APACHE II scores at entry all adversely affected the eradica-
35 (17-3) 29 (14.5) tion rate. By using these three variables, stepwise logistic
regression was employed to develop the most predictive model
for response to treatment. The final model chosen by the
75 (37.1) 73 (36.5) stepwise procedure included all three variables which were
predictive in the univariate analyses. When treatment group
127 (62.9) 127 (63.5) was added to this model, ciprofloxacin therapy resulted in a
bacteriological eradication rate significantly superior (P =
t the time of randomization into the 0.039) to that of imipenem therapy (Table 4).
treatment groups were statistically Clinical resolution rates in the efficacy-evaluable population
also were analyzed by logistic regression to determine whether
on gradient. ciprofloxacin was statistically superior to imipenem, even when
actional inspired oxygen concentra- other potentially confounding factors were simultaneously
considered. In the univariate analyses, the requirement for
atment group had nonpulmonary mechanical ventilation, a higher leukocyte count, a higher
APACHE II score, and presence of P. aeruginosa at entry all
wntensive care unit were found to have a statistically significant adverse impact on
the resolution rate. Since leukocyte count is a component of
the APACHE II score, only the APACHE II score was
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TABLE 3. Efficacy assessments
No. of patients with respiratory No. of patients with clinical
bacteriological eradication,'/total (%) 95% CI (%) for all resolutionbx/total (%) 95% CI for all
Population and pneumoniaC pneumonia
treatment group Nosocomial Community- All (P value)d Nosocomial .cquity- All value)"
acquired ~~~~~~~~~~acquiredvuepneumonia a pneumonia pneumonia pneumonia pneumoniapneumonia pneumonia
Efficacy evaluable
Ciprofloxacin 57/83 (69) 9/12 (75) 66/95 (69) -0.6, 26.2 (0.069) 58/86 (67) 10/12 (83) 68/98 (69) 3.5, 28.5 (0.021)
Imipenem 44/76 (58) 11/18 (61) 55/94 (59) 44/83 (53) 14/21 (67) 58/104 (56)
Intent to treat
Ciprofloxacin 63/97 (65) 13/18 (72) 76/115 (66) -0.9, 24.2 (0.077) 74/121 (61) 18/23 (78) 92/144 (64) -2.1, 19.6 (0.123)
Imipenem 53/96 (55) 13/20 (65) 66/116 (57) 71/130 (55) 19/32 (59) 90/162 (56)
Eradication rate = (number of patients with eradication + presumed eradication)/(number of patients with eradication + presumed eradication + persistence) (4).b These data do not include indeterminate responses; therefore, the denominators differ for different parameters.
CI, 95% CI for difference in eradication (or resolution) rates (ciprofloxacin minus imipenem).
d P values (two tailed) were calculated by the Cochran-Mantel-Haenszel method.
e Resolution rate = (resolution + improvement)/(resolution + improvement + failure) (8).
considered in the development of the stepwise logistic regres-
sion model. The final model chosen by the multivariate proce-
dure included all three variables which were significant univa-
riate predictors. When treatment group was added to this
multiple logistic regression model, it continued to have a
statistically significant effect on the resolution rate (Table 4).
Thus, even after adjustment for confounding variables, clinical
outcome in the ciprofloxacin treatment group was statistically
superior to that in the imipenem treatment group (P = 0.016).
Pathogenic organisms. The spectrum of organisms isolated
from the respiratory tract at study entry was similar in the two
treatment groups for both the efficacy-evaluable and the
intent-to-treat populations (data not shown). The most com-
mon isolates encountered in the intent-to-treat population
were P. aeruginosa (n = 91), H. influenzae (n = 72), methicil-
lin-susceptible S. aureus (n = 60), Klebsiella pneumoniae (n =
46), and Escherichia coli (n = 30). The frequency of E. cloacae
and K pneumoniae isolates was greater in the imipenem
treatment group than in the ciprofloxacin treatment group (16
versus 7 for E. cloacae and 29 versus 17 for K pneumoniae,
respectively); these differences were not statistically significant.
In the intent-to-treat population, 94.1% of the organisms
isolated at study entry were susceptible in both the ciprofloxa-
cin and imipenem treatment groups, and in the efficacy-
evaluable population, 98.6 and 96.5% of the organisms isolated
from ciprofloxacin- and imipenem-treated patients, respec-
tively, were susceptible at entry (32, 33).
The bacteriological eradication rates for each causative
organism at the respiratory site are shown in Table 5. Overall,
the ciprofloxacin treatment group showed a higher rate of
TABLE 4. Analysis of risk factors for favorable bacteriological and clinical responses in efficacy-evaluable patients: a logistic regression model
Bacteriological response Clinical response
Risk factor' Univariate Stepwise logistic regression Univariate Stepwise logistic regression
P value" P valueb Odds 95% CI for P value* P value rtOdds 95% CI forratio' odds ratio ratio' odds ratio
Aged 0.829 0.816
Sex 0.366 0.920
Higher body wtd 0.010 0.011 1.03 1.01, 1.05 0.628
Race 0.824 0.581
Diagnosis of nosocomial pneumonia 0.742 0.183
Days in hospital prior to enrollmentd 0.294 0.322
Mechanical ventilation not required 0.637 0.001 0.001 8.06 2.31, 28.06
Lower APACHE II scored 0.007 0.027 1.07 1.01, 1.13 0.019 0.058 1.05 0.99, 1.11
Alveolar-arterial oxygen tension 0.470 0.859
gradientd
PaO2/FIO2 ratiode 0.379 0.266
PEEPdf 0.734 0.150
Serum creatinined 0.919 0.371
Lower leukocyte countd 0.129 0.021
Multiple respiratory pathogens 0.141 0.204
Absence of P. aeruginosa 0.0001 0.0001 7.12 3.35, 15.14 0.008 0.011 2.38 1.22, 4.65
Treatment with ciprofloxacin 0.039 2.08 1.04, 4.16 0.016 2.16 1.15, 4.03
a Variable as present at study randomization.
"P value (two-tailed) calculated by the Wald chi-square method.
By definition, an odds ratio of 1.0 means the two groups are equal. An odds ratio of > 1.0 means that the chance of bacteriological or clinical success is greater for
the situation described.
d Treated as a continuous variable.
' PaO2, arterial oxygen tension; F102, fractional inspired oxygen concentration.
f PEEP, positive end-expiratory pressure.
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TABLE 5. Bacteriological eradication rates for each causative organism at respiratory site'
No. of organisms eradicated/total (%)
Organism Efficacy-evaluable population Intent-to-treat population
Ciprofloxacin group Imipenem group Ciprofloxacin group Imipenem group
(n = 152)' (n = 155)" (n = 177)b (n = 182)'
S. aureus
Methicillin susceptible 13/20 (65) 11/17 (65) 15/26 (58) 14/20 (70)
Methicillin resistant 0/0 (0) 1/1 (100) 0/0 (0) 2/2 (100)
S. pneumoniae 8/8 (100) 5/5 (100) 9/9 (100) 9/9 (100)
H. influenzae 25/25 (100) 18/18 (100) 29/29 (100) 22/24 (92)
Acinetobacter species 5/6 (83) 4/5 (80) 5/6 (83) 4/5 (80)
E. coli 10/10 (100) 11/14 (79) 10/10 (100) 11/14 (79)
Klebsiella species 10/11 (91) 12/18 (67) 13/17 (76) 13/21 (62)
Proteus species 6/6 (100) 2/5 (40) 6/6 (100) 2/5 (40)
Enterobacter species 10/10 (100) 13/21 (62) 10/10 (100) 13/22 (59)
P. aeruginosa 11/33 (33) 11/27 (41) 13/38 (34) 11/32 (34)
X maltophilia 0/2 (0) 0/2 (0) 0/2 (0) 0/2 (0)
Other gram-positive coccic 3/4 (75) 2/2 (100) 4/6 (67) 2/2 (100)
Other gram-negative bacillid 11/13 (85) 10/14 (71) 12/14 (86) 12/16 (75)
Other' 4/4 (100) 5/6 (83) 4/4 (100) 5/8 (63)
Total 116/152 (76) 105/155 (68) 130/177 (73) 120/182 (66)
a The data do not include indeterminate responses; therefore, denominators change for different parameters. Eradication rate = (eradication + presumed
eradication)/(eradication + presumed eradication + persistence) (4).
b n, number of organisms at entry; one patient may have had more than one type of bacteria isolated.
C Enterococcus and other Streptococcus species.
d Citrobacter species, Hafnia alvei, Morganella morganii, Providencia species, Serratia marcescens, Aeromonas hydrophila, Pseudomonas fluorescens, P. paucimobilis,
Eikenella corrodens, and Haemophilus parainfluenzae.
e Neisseria, Moraxella, and Corynebacterium species.
pathogen eradication than did the imipenem treatment group
for both the efficacy-evaluable population (76 versus 68%,
respectively) and the intent-to-treat population (73 versus
66%, respectively). This was primarily due to the statistically
superior ability of ciprofloxacin to eradicate members of the
family Enterobacteriaceae (41 of 44 [93%] for ciprofloxacin
versus 45 of 68 [66%] for imipenem; P = 0.001) in the
efficacy-evaluable population. The two antimicrobial agents
were comparable with regard to eradication of S. aureus, H.
influenzae, S. pneumoniae, and P. aeruginosa, for both the
efficacy-evaluable and the intent-to-treat populations. In both
treatment groups, bacteriological failure was common when P.
aeruginosa was a pretreatment respiratory pathogen. In the
efficacy-evaluable population, bacteriological eradication of P.
aeruginosa was greater, but not significantly so, in the imi-
penem group than in the ciprofloxacin group (11 [41%] versus
11 [33%], respectively; P = 0.559).
Development of resistance. The development of bacteriolog-
ical resistance by organisms that were initially susceptible to
the study antimicrobial agents is shown in Table 6. In the
intent-to-treat population, both treatment groups exhibited
similar rates of development of resistance: 9% for the cipro-
floxacin treatment group and 11% for the imipenem treatment
group. There were 23 isolates from 20 ciprofloxacin-treated
patients and 27 isolates from 27 imipenem-treated patients
that developed resistance during the course of the study in the
intent-to-treat population. P. aeruginosa was the predominant
pathogen developing resistance to ciprofloxacin or imipenem
in both the intent-to-treat and efficacy-evaluable patients. For
this organism, 13 (28%) of 47 isolates in the ciprofloxacin
treatment group and 22 (50%) of 44 isolates in the imipenem
treatment group developed resistance in the intent-to-treat
population. Resistance to P. aeruginosa did not develop before
day 3 of treatment, but by day 7 of therapy, 6 (of 13) isolates
in the ciprofloxacin treatment group and 13 (of 22) isolates in
the imipenem treatment group had become resistant.
Superinfection. Superinfection was caused by 21 isolates in
18 ciprofloxacin-treated patients and by 37 isolates in 30
imipenem-treated patients in the efficacy-evaluable popula-
tion. In the intent-to-treat population, superinfection was
caused by 32 isolates in 28 ciprofloxacin-treated patients and
caused by 53 isolates in 41 imipenem-treated patients. Al-
though certain species of superinfecting organisms seemed to
be study drug specific, P. aeruginosa, K pneumoniae, and
Xanthomonas maltophilia were the primary pathogens causing
superinfection in the efficacy-evaluable population (Table 6).
Premature discontinuation from study treatment. Treat-
ment with the study drug was discontinued prematurely for 192
of 402 patients; of these, 96 were in the ciprofloxacin treatment
group and 96 were in the imipenem treatment group. Reasons
for premature drug discontinuation were as follows (the per-
centages of all patients in the ciprofloxacin and imipenem
treatment groups, respectively, are in parentheses): failure to
respond clinically (12 and 20% [P = 0.032]), violation of
inclusion or exclusion criteria (14 and 7% [P = 0.020]), death
(5 and 3% [P = 0.332]), adverse reaction (3 and 5% [P =
0.575]), and miscellaneous factors (12 and 14% [P = 0.695]).
Adverse events. Adverse events were reported for 132 (65%)
of 202 patients in the ciprofloxacin treatment group and for
148 (74%) of 200 patients in the imipenem treatment group, a
difference that was not statistically significant (P = 0.059).
However, seizures occurred in only 3 (1%) of 202 patients in
the ciprofloxacin treatment group, compared with 11 (6%) of
200 patients in the imipenem treatment group (P = 0.028). In
two ciprofloxacin-treated patients, seizures occurred more
than a week after the study drug was discontinued. In contrast,
all seizures in the imipenem treatment group occurred during
therapy with imipenem. Myocardial infarction occurred in 2%
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TABLE 6. Superinfection and development of bacterial resistance
No. of organisms/total (cl%)
Organism(s) Efficacy-evaluable population Intent-to-treat population
Ciprofloxacin Imipenem Ciprofloxacin Iniipenem
Resistance developed"
P. aeruginosa 12/36 (33) 17/32 (53) 13/47 (28) 22/44 (50)
Methicillin-susceptible S. aureus 5/20 (25) 3/19 (16) 6/33 (18) 3/27 (11)
Othere 2/7 (29) 1/3 (33) 4/45 (9) 2/72 (3)
Superinfcctionc
K pneumoniae 4/21 (19) 4/37 (11) 5/32 (16) 6/53 (11)
P. aeruginosa 1/21 (5) 7/37 (19) 2/32 (6) 9/53 (17)
X. maltophilia 1/21 (5) 5/37 (13) 1/32 (3) 7/53 (13)
Methicillin-susceptible S. aureus 3/21 (14) 2/37 (5) 5/32 (16) 2/53 (4)
E. cloacae 0/21 (0) 4/37 (11) 1/32 (3) 4/53 (8)
Acinetobacter calcoaceticuis 3/21 (14) 1/37 (3) 3/32 (9) 1/53 (2)
Other" 9/21 (43) 14/37 (38) 15/32 (47) 24/53 (45)
"Number of organisms that developed resistance/number of organisms present at entry.
' Klebsiella pncumontiiac, Eniterobacter cloacae, Serratia tmarcescenis, group C streptococci, Citrobacter diversus, and Enlteruobacter aeL'ogenes.
'Number of organisms responsible for superinfection/total cases of superinfection for the treatment group.
"Escherichia coli, Enterobacter aerogenes, Klebsiella oxvtoca, Proteus mirabilis, Pseudonionas cepacia, group B streptococci, Pseudomonias fluorescenis, Haenrojphilus
influenzae, methicillin-resistant Staphylococcus auireus, coagulase-positive staphylococci, Achromobacter-xlosoxidans, Acinietobacter baumanniii (aniitratus), Chromoobac-
terium violaceuin, Serratia species, Streptococcus pnelimouoiae, coagulase-negative staphylococci, Bacteroides fragilis, Huenioplhilus parainifluenzae, Candidla species,
Serratia marcescenis, Streptococcus viridans, Enterococcus species, Flavobacterium meninigosepticum, and Aerococcus ti'ridans.
of imipenem patients but not at all in the ciprofloxacin
treatment group (P = 0.030). Other adverse events occurred
with similar frequencies in both treatment groups.
Changes in laboratory values of possible clinical significance
that occurred with significantly different frequencies in the two
treatment groups included hematocrit decreases (55% of
ciprofloxacin-treated patients versus 65% of imipenem-treated
patients), uric acid decreases (36 versus 49%), and blood urea
nitrogen elevations (24 versus 13%). In addition, 38 and 39%
of the ciprofloxacin- and imipenem-treated patients, respec-
tively, who were receiving concomitant theophylline had in-
creases in levels of theophylline in serum of -25% from the
baseline at some time during the study. However, toxicity was
not ascribed to theophylline by any investigator.
Mortality. There were 81 (20%) deaths in the intent-to-treat
population while patients received the study drug or within the
30-day posttherapy period.
During the first 48 h after study entry, 11 patients (4
imipenem- and 7 ciprofloxacin-treated patients) died. P.
aeruginosa was isolated from one of the ciprofloxacin-treated
patients and one of the imipenem-treated patients who died
within the first 48 h of therapy. P. aeruginosa was isolated on
initial culture from 19 (23%) of the 81 patients who died, and
only 2 (3%) of these patients died within the first 48 h of the
study.
Of the 81 deaths that occurred, 43 were in the ciprofloxacin
treatment group and 38 were in the imipenem treatment group
(P = 0.619). Eighteen of the 43 deaths in the ciprofloxacin
treatment group were attributed to the patients' underlying
disease(s), 23 were attributed to bacterial infection, and 2 were
considered indeterminate. In the imipenem treatment group,
21 deaths were attributed to an accompanying disease(s), 15
were attributed to bacterial infection, and 2 were considered
indeterminate. As stated previously, these assignments were
made by the investigators prior to unblinding of the study. The
difference in the number of deaths attributed to bacterial
infection in the ciprofloxacin versus the imipenem treatment
group was not statistically significant (P = 0.199).
DISCUSSION
Parenterally administered antimicrobial agents remain the
cornerstone of therapy for severe pneumonia. Although nu-
merous clinical studies have compared various antimicrobial
regimens for the treatment of pneumonia, the ability to draw
meaningful conclusions regarding the relative efficacy or safety
of the agents being evaluated has often been compromised by
aspects of trial design or the way results were analyzed and
reported. Previous trials often excluded critically ill patients,
especially those requiring mechanical ventilation or with se-
vere renal or hepatic dysfunction (16, 17, 43). Most previous
trials have employed nonblind study designs (15, 16, 23, 27, 48,
49), lacked an intent-to-treat analysis (16, 27), suffered from
small patient sample sizes (39-41, 44), or enrolled patients with
other infections in addition to pneumonia (21, 23, 27, 48, 49).
This is the first large, randomized, double-blind comparative
antimicrobial clinical trial utilizing a rigorous prospective study
design with patients with severe pneumonia of which we are
aware. Among the strengths of this study were the use of
double-blind treatment assignment, analysis of predetermined
endpoints before unblinding of the treatment allocation code,
and enrollment of patients on the basis of severity of illness.
This yielded a large, well-characterized, relatively homoge-
neous population of seriously ill patients, as evidenced by the
large proportion requiring mechanical ventilation and the high
initial APACHE II scores. Efficacy analyses of the data were
performed for both the efficacy-evaluable and the intent-to-
treat populations of patients.
The primary endpoint of this study was eradication of the
pretreatment respiratory pathogen(s). Although the difference
is not quite statistically significant by univariate analysis,
treatment with ciprofloxacin resulted in a 10% higher bacteri-
ological eradication rate than that observed in the imipenem-
treated patients. The difference in bacteriological outcome was
due mainly to the significantly higher eradication rate among
members of the family Enterobacteriaceae in the ciprofloxacin
treatment group. By using multivariate analysis to control for
the presence of P. aeruginosa at initiation of therapy, patient
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weight, and APACHE II score, ciprofloxacin therapy resulted
in a bacteriological eradication rate significantly superior to
that achieved with imipenem.
In this large, multicenter study, we have also shown that
monotherapy with i.v. ciprofloxacin was superior to imipenem
with respect to clinical efficacy in the efficacy-evaluable patient
population. Furthermore, even after adjustment for potentially
confounding factors highly associated with clinical failures,
such as ventilator dependence, APACHE II score, and the
presence of P. aeruginosa in the pretreatment sputum culture,
ciprofloxacin treatment was significantly superior to imipenem
in clinical efficacy, according to stepwise logistic regression
analysis. In the intent-to-treat analysis, the difference in effi-
cacy between the two treatment regimens did not quite reach
significance.
A major clinical question is whether the use of a single
antibiotic is sufficient for treatment of severe bacterial pneu-
monia in seriously ill patients, especially if the infection is with
a nosocomially acquired gram-negative bacillus. The results
presented here suggest that monotherapy is adequate for
treatment of most cases of serious community- and hospital-
acquired pneumonia, even in ventilator-dependent patients,
unless the causative organism is P. aeruginosa. If cases with P.
aeruginosa are excluded, the bacteriological eradication rates
for the ciprofloxacin and imipenem treatment groups are 86
and 66%, respectively. Although some patients did receive
concomitant antimicrobial agents, these agents did not gener-
ally overlap the spectrum of either study drug.
The importance of P. aeruginosa as a respiratory pathogen
associated with severe illness and poor outcome is underscored
by our stepwise logistic regression analysis, which indicates that
the risk of clinical failure with either study drug was approxi-
mately double when this organism was cultured prior to
institution of therapy. Of the P. aeruginosa strains which were
susceptible to ciprofloxacin and imipenem prior to therapy, 33
and 53%, respectively, developed resistance during the trial in
the efficacy-evaluable population. Even combination therapy
with two appropriate antipseudomonal antibiotics may not
result in clinical cure, lead to eradication of the organism, or
prevent development of resistance (3, 36). In our study, for
two-thirds of patients for whom study drug therapy failed, the
failure was still evident at the 14- to 28-day posttherapy
evaluation, despite the use of subsequent nonstudy antimicro-
bial agents. Nevertheless, in view of the overall increased
likelihood of treatment failure or development of resistance
reported in the literature and confirmed by this study, mono-
therapy with either imipenem or ciprofloxacin cannot be
recommended for the treatment of pneumonia when P. aerugi-
nosa is isolated. Although there are data that support the use
of more than one antipseudomonal agent for the treatment of
P. aeruginosa bacteremia (22), it is noteworthy that in no
patient in this study with P. aeruginosa did resistance to either
treatment regimen develop earlier than 3 days after initiation
of treatment. Furthermore, the proportion of early deaths
associated with pretherapy isolation of P. aeruginosa was not
different from that associated with other organisms. Therefore,
when a patient develops severe pneumonia, initial empiric
antibiotic therapy with a single potent, broad-spectrum agent is
reasonable until culture results are obtained. If P. aeruginosa is
isolated, then the use of combination therapy appears to be
prudent to avoid the emergence of resistance, although routine
use of combination antibiotics for severe pneumonia may
increase the risk of toxicity or superinfection (24).
There are some limits to this study. Recent data suggest that
the clinical criteria used to diagnose pneumonia lack specificity
(2, 13, 42, 45, 46). Although strict diagnostic criteria were
employed, newer invasive diagnostic methods, such as use of a
protected specimen brush or bronchoalveolar lavage, were not
routinely employed in this study. However, our entry criteria
were those which most clinicians would still employ to make a
diagnosis of pneumonia and are consistent with recently
published guidelines for the conduct of clinical studies for
anti-infective agents (4, 8). While some invasive diagnostic
procedures may eventually gain wider acceptance, they are not
routinely used to make a bacteriological or clinical diagnosis in
most institutions. Furthermore, few data that demonstrate a
clear diagnostic or prognostic benefit for these procedures are
available (9, 35).
In addition, it must be emphasized that our study population
was not necessarily representative of all patients with severe
pneumonia. This was primarily because many of the investiga-
tors who participated in the study were intensivists or pulmo-
nologists in charge of intensive care units. Nevertheless, the
results described here are probably generalizable to most
patients with severe pneumonia, especially those receiving
mechanical ventilation.
The only two adverse events of statistical significance were
seizures and myocardial infarction. Both ciprofloxacin and
imipenem have been associated with central nervous system
side effects, such as seizures (1, 25). In the present study,
seizures occurred significantly more frequently among patients
treated with imipenem than among those treated with cipro-
floxacin, despite an equal distribution of predisposing condi-
tions. The occurrence of myocardial infarction, although not
explainable, was limited to the imipenem treatment group.
In summary, this multicenter, prospective, randomized,
blinded, controlled trial demonstrated that ciprofloxacin is
superior to imipenem with respect to the clinical response of
patients and equivalent to imipenem with respect to eradica-
tion of pulmonary pathogens in patients with severe pneumo-
nia. The major risk factors for failure of bacteriological
eradication were presence of P. aeruginosa, a low body weight,
and a high APACHE II score. Risk factors for clinical failure
with either regimen also included a high APACHE II score
and the presence of P. aeruginosa in the pretreatment culture,
as well as ventilator dependence. Antibiotic monotherapy can
be used successfully to treat severe pneumonia; however, this
study clearly demonstrates that additional strategies are nec-
essary to treat pneumonia associated with P. aeruginosa,
although initial monotherapy appears to be safe for 48 h, until
culture results are obtained.
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